Virtual Library
Start Your Search
Jing Zhang
Author of
-
+
P2.12 - Small Cell Lung Cancer/NET (ID 180)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.12-12 - Nomograms to Predict Survival in Patients with Limited Stage Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy (Now Available) (ID 299)
10:15 - 18:15 | Author(s): Jing Zhang
- Abstract
Background
To build nomograms to predict progression-free survival (PFS) as well as overall survival (OS) in patients with limited stage small cell lung cancer (LS-SCLC) treated with definitive chemoradiation.
Method
A total of 170 patients treated with chemotherapy and hypo- (HypoTRT) (n = 69) or conventionally (ConvTRT) (n = 101) fractionated radiotherapy between 2010 and 2013 were included. Primary endpoints were progression-free survival (PFS) and overall survival (OS). The prognostic effects of variables were analyzed using Kaplan–Meier method and Cox regression model. Nomograms were established for estimating 1-, 2- and 3-year OS and PFS based on Cox regression model. The utility of the proposed model was evaluated using the time-dependent ROC and area under ROC (AUC).
Result
The survival analysis showed no difference between HypoTRT and ConvTRT combined with chemotherapy. However, regard with the chemoradiotherapy (CRT) modality, the median PFS and OS were 19.4 and 33.0 months in the concurrent group, which was significantly better than those in the sequential group (PFS 12.2 months, p=0.012, OS 20.1 months, p<0.001). According to the multivariate analysis, the final nomograms for OS and PFS were developed. Two nomograms shared common variables including gender, CRT modality, prophylactic cranial irradiation (PCI) and TNM stage, while age at diagnosis, smoking status and chemotherapy circle were only incorporated in the OS nomogram. Nomograms showed better performance than TNM algorithm (3-year AUC for OS: TNM, 0.569; nomogram, 0.832; 3-year AUC for PFS: TNM, 0.572; nomogram, 0.761).
Conclusion
Our nomograms are reliable and powerful tools for distinguishing and predicting the survival of LS-SCLC treated with definitive chemoradiation, thus helping to better select medical examinations and optimize treatment options in collaboration with medical oncologists.
